NCT01654965View on ClinicalTrials.gov

Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 24, 2012

Primary Completion Date

March 29, 2018

Study Completion Date

March 29, 2018

Conditions
Adult Solid Neoplasm
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pegfilgrastim

Given SC

OTHER

Pharmacological Study

Correlative studies

DRUG

Tivantinib

Given PO

DRUG

Topotecan Hydrochloride

Given IV

Trial Locations (7)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

48201

Wayne State University/Karmanos Cancer Institute, Detroit

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

95817

University of California Davis Comprehensive Cancer Center, Sacramento

17033-0850

Penn State Milton S Hershey Medical Center, Hershey

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01654965 - Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter